🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-521752-26-00
Completed Phase II

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

2025-521752-26-00 · tracked via the Priya Life Science EU tracker
Sponsor
Adarx Pharmaceuticals Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Male Urogenital Diseases
Decision date
02/03/2026
Enrollment target
7
Sites
Spain, Italy

Condition studied

Complement-Mediated Kidney Disease

Investigational medicinal product(s)

Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups ACW-135 and Y conjugate vaccineNimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups ACW-135 and Y conjugate vaccineInfanrix hexaPowder and suspension for suspension for injection. Diphtheria (D)tetanus (T)pertussis (acellularcomponent) (Pa)hepatitis B (rDNA) (HBV)poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNAcomponentadsorbed)Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups ACW-135 and Y conjugate vaccineInfanrix hexaPowder and suspension for suspension for injection. Diphtheria (D)tetanus (T)pertussis (acellularcomponent) (Pa)hepatitis B (rDNA) (HBV)poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).ADX-038Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNAcomponentadsorbed)Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNAcomponentadsorbed)Infanrix hexaPowder and suspension for suspension for injection. Diphtheria (D)tetanus (T)pertussis (acellularcomponent) (Pa)hepatitis B (rDNA) (HBV)poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNAcomponentadsorbed)Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups ACW-135 and Y conjugate vaccinePrevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valentadsorbed)Infanrix hexaPowder and suspension for suspension for injection. Diphtheria (D)tetanus (T)pertussis (acellularcomponent) (Pa)hepatitis B (rDNA) (HBV)poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valentadsorbed)Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valentadsorbed)Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valentadsorbed)

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Incidence and severity of TEAEs

Endpoint detail

1. Change from baseline in UPCR as measured by 24-hour urine over time, 2. Change from baseline in UPCR as measured by spot urine over time

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521752-26-00 on CTIS ↗ ← All trials in the EU